
Hepatitis A Virus





Hepatitis A - Clinical Features

- Incubation period:
- Jaundice by age group:
- Complications:

Chronic sequelae:

Average 30 days Range 15-50 days

<6 yrs, <10% 6-14 yrs, 40%-50% >14 yrs, 70%-80%

Fulminant hepatitis
Cholestatic hepatitis
Relapsing hepatitis

None




Age-specific Mortality Due to Hepatitis A

Age group (years)	Case-Fatality (per 1000)	
<5	3.0	
5-14	1.6	
15-29	1.6	
30-49	3.8	
>49	17.5	
Total	4.1	




Source: Viral Hepatitis Surveillance Program, 1983-1989





Concentration of Hepatitis A Virus in Various Body Fluids



Infectious Doses per ml

Source: Viral Hepatitis and Liver Disease 1984;9-22

J Infect Dis 1989;160:887-890




Hepatitis A Virus Transmission

- Close personal contact

 (e.g., household contact, sex contact, child day care centers)
- Contaminated food, water
 (e.g., infected food handlers, raw shellfish)
- Blood exposure (rare)
 (e.g., injecting drug use, transfusion)




Incidence of Hepatitis A, United States, 1952-1993




Source: CDC, National Notifiable Diseases Surveillance System



Age-specific Incidence of Hepatitis A United States, 1983-93



Source: CDC, National Notifiable Diseases Surveillance System




Source: CDC, Viral Hepatitis Surveillance Program

Global Patterns of Hepatitis A Virus Transmission

Endemicity	Disease Rate	Peak Age of Infection	Transmission Pattern
High	Low to High	Early childhood	Person to person; outbreaks uncommon
Moderate	High	Late childhood/ young adults	Person to person; food and waterborne outbreaks
Low	Low	Young adults	Person to person; food and waterborne outbreaks
Very low	Very low	Adults	Travelers; outbreaks uncommon

Geographic Distribution of HAV Infection



Hepatitis A Vaccine Efficacy Studies

<u>Vaccine</u>	Site/Age Group	N	Vaccine Efficacy (95% CI)
HAVRIX ^Ò (SKB) 2 doses 360 EL.U.	Thailand 1-16 yrs	38,157	94% (79%-99%)
VAQTA ä (Merck) 1 dose 25 units	New York 2-16 yrs	1,037	100% (85%-100%)

JAMA 1994;271:1363-4 N Engl J Med 1992;327:453-7



Hepatitis A Vaccination Strategies Epidemiologic Considerations

- Many cases occur in community-wide outbreaks
 - no risk factor identified for most cases
 - highest attack rates in 5-14 year olds
 - children serve as reservoir of infection
- Persons at increased risk of infection
 - travelers
 - homosexual men
 - injecting drug users



Routine Childhood Hepatitis A Vaccination

Benefits

- established delivery system
- vaccination before risk period
- potential to interrupt transmission

Unresolved issues/considerations

- immunogenicity in infants
- development of combination vaccines
- duration of protection
- cost-effectiveness



ACIP Recommendations - Hepatitis A Vaccine Preexposure Vaccination

- Persons at increased risk for infection
 - travelers to intermediate and high HAV-endemic countries
 - homosexual and bisexual men
 - drug users
 - persons with chronic liver disease
- Communities with high rates of hepatitis A (e.g., Alaska Natives, American Indians)
 - routine childhood vaccination



Features of Community-wide Hepatitis A Outbreaks

Type of Community	Anti-HAV Prevalence	Usual Age of Case- patients	Annual Incidence/ 100,000	Outbreak Periodicity	Populations
High rate	<5 yrs old 30%-40% >15 yrs old 70% -100%	5-14 yrs	700-1000	5-10yrs	well defined geographically or ethnically
Intermediate rate	<5 yrs old 10%-25% >15 yrs old <50%	5-29 yrs	50-200	may be periodic	less defined than in high-rate communities



ACIP Recommendations - Hepatitis A Vaccine Control of Community-wide Outbreaks

High-rate communities

- Routine vaccination of young children
- Accelerated catch-up vaccination of older children



ACIP Recommendations - Hepatitis A Vaccine Control of Community-wide Outbreaks

Intermediate-rate communities

- Targeted vaccination can be considered for groups or areas with highest disease rates (e.g., specific age groups, census tracts, drug users)
- Factors to consider:
 - feasibility of vaccinating target groups
 - program cost
 - ability to sustain vaccination of young children



ACIP Recommendations - Hepatitis A Vaccine Prevaccination Testing

Considerations:

- cost of vaccine
- cost of serologic testing (including visit)
- prevalence of infection
- impact on compliance with vaccination

Likely to be cost-effective for:

- adults born, or who lived in, high endemic areas
- adults >40 years of age
- older adolescents and young adults in certain groups
 (American Indians, Alaska Natives, Pacific Islanders)



ACIP Recommendations - Hepatitis A Vaccine Postvaccination Testing

- Not recommended because of the high response rate among vaccinees
- No commercially available test to measure vaccine response



Recommended Doses and Schedules of Hepatitis A Vaccine

	HAVRIX ^â			
Age	No. Doses	Doses EL.U.* (ml)	Schedule (months)	
2-18 years	3	360 (0.5)	0, 1, 6-12	
>18 years	2	1,440 (1.0)	0, 6-12	
	2-18 years	Age Doses 2-18 years 3	Age No. Doses EL.U.* (ml) 2-18 years 3 360 (0.5)	





Hepatitis A Prevention - Immune Globulin

- Preexposure
 - travelers to intermediate and high HAV-endemic regions
- Postexposure (within 14 days)
 - Routine
 - household and other intimate contacts
 - Selected situations
 - institutions (e.g., day care centers)
 - common source exposure (e.g., food prepared by infected food handler)

